Repository logo
 
Publication

An estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costs

2017-01Conference object Open access
Simple item page
dc.contributor.authorAguiar, Pedro, Jr.
dc.contributor.authorDe Mello, Ramon Andrade
dc.contributor.authorTadokoro, Hakaru
dc.contributor.authorBabiker, Hani
dc.contributor.authorLopes, Gilberto
dc.date.accessioned2019-11-20T15:07:59Z
dc.date.available2019-11-20T15:07:59Z
dc.date.issued2017-01
dc.description.abstractDelivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.
dc.description.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.urihttp://hdl.handle.net/10400.1/13305
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier Science
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleAn estimate of the economic impact of immunotherapy relative to PD-L1 expression in Brazil - An update with brazilian costs
dc.typeconference object
dspace.entity.typePublication
oaire.citation.endPageS427
oaire.citation.issue1
oaire.citation.startPageS427
oaire.citation.titleJournal of Thoracic Oncology
oaire.citation.volume12
person.familyNamede Mello
person.givenNameRamon Andrade
person.identifier.orcid0000-0002-9640-4573
rcaap.rightsrestrictedAccess
rcaap.typeconferenceObject
relation.isAuthorOfPublication53ee625f-c5c3-468b-85bb-4cef5ad36928
relation.isAuthorOfPublication.latestForDiscovery53ee625f-c5c3-468b-85bb-4cef5ad36928

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S1556086416317361-main.pdf
Size:
92.06 KB
Format:
Adobe Portable Document Format
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)